Non-RhD (anti-E) red cell alloimmunization following platelet transfusion: a case report and implications on quality of the platelet concentrates and antibody screening protocols

Subramaniyan, Rajeswari

doi:10.1016/j.htct.2020.08.009

Cited by 1 publication

(1 citation statement)

References 8 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Moreover, the presence of clinically significant anti-D antibodies can lead to delays in transfusions, further complicating the identification of compatible blood. Table 2 tabulates a summary of clinical and laboratory findings recorded in published instances of alloimmunization arising from plasma transfusion [ 7 - 9 ]. McLeod et al's research indicated that immunosuppressed patients had the highest occurrence of anti-D alloimmunization after receiving D-incompatible platelet transfusions, while in immunocompetent individuals, the production of anti-D typically occurred within approximately 1-5 months [ 10 ].…”

Section: Discussionmentioning

confidence: 99%

Anti-D Alloimmunization Following Rhesus-Incompatible Platelet Transfusion in a Myelodysplastic Syndrome Patient

Hanafi,

Zulkeflee,

Hassan

et al. 2024

Cureus

View full text Add to dashboard Cite

Patients with myelodysplastic syndrome (MDS) often need platelet transfusions to address thrombocytopenia. The risk of alloimmunization, particularly in Rhesus (Rh) incompatibility between donors and recipients during platelet transfusions, is heightened, especially with whole blood-derived pooled platelets as opposed to apheresis platelets. Although the occurrence of alloimmunization from platelet transfusions is minimal, there is an ongoing debate about whether Rh immune globulin (RhIg) should be administered to Rhesus D (RhD)-negative recipients of RhD-positive platelet units. We present a unique case of anti-D alloimmunization in a 56-year-old patient with underlying MDS following multiple platelet transfusions but never received packed cell transfusion or anti-D immunoglobulin. Some studies advocate for RhIg administration in specific scenarios and for certain patient populations. This case underscores the importance of considering Rhesus compatibility or administering anti-D immunoglobulin in cases where frequent platelet transfusions are required.

show abstract

Section: Discussionmentioning

confidence: 99%